Esperion Therapeutics Inc’s recently made public that its President and CEO Koenig Sheldon L. unloaded Company’s shares for reported $0.18 million on Dec 17 ’25. In the deal valued at $3.67 per share,48,244 shares were sold. As a result of this transaction, Koenig Sheldon L. now holds 1,470,587 shares worth roughly $5.43 million.
Then, Halladay Benjamin sold 7,337 shares, generating $26,905 in total proceeds. Upon selling the shares at $3.67, the Chief Financial Officer now owns 467,525 shares.
Before that, Looker Benjamin sold 6,517 shares. Esperion Therapeutics Inc shares valued at $23,898 were divested by the General Counsel at a price of $3.67 per share. As a result of the transaction, Looker Benjamin now holds 385,905 shares, worth roughly $1.42 million.
Piper Sandler initiated its Esperion Therapeutics Inc [ESPR] rating to an Overweight in a research note published on November 25, 2025; the price target was $9. A number of analysts have revised their coverage, including Goldman’s analysts, who began to cover the stock in mid December with a ‘”a Neutral”‘ rating. Cantor Fitzgerald began covering ESPR with “an Overweight” recommendation on December 17, 2024. BofA Securities revised its rating on June 20, 2024. It rated ESPR as “an Underperform” which previously was an “a Neutral”.
Price Performance Review of ESPR
On Tuesday, Esperion Therapeutics Inc [NASDAQ:ESPR] saw its stock fall -5.14% to $3.69. Over the last five days, the stock has lost -8.66%. Esperion Therapeutics Inc shares have risen nearly 59.05% since the year began. Nevertheless, the stocks have risen 67.73% over the past one year. While a 52-week high of $4.13 was reached on 12/23/25, a 52-week low of $0.69 was recorded on 05/15/25.
Levels Of Support And Resistance For ESPR Stock
The 24-hour chart illustrates a support level at 3.61, which if violated will result in even more drops to 3.52. On the upside, there is a resistance level at 3.85. A further resistance level may holdings at 4.00.
How much short interest is there in Esperion Therapeutics Inc?
A steep rise in short interest was recorded in Esperion Therapeutics Inc stocks on 2025-12-15, growing by 3.87 million shares to a total of 28.83 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-14 was 24.96 million shares. There was a rise of 13.42%, which implies that there is a positive sentiment for the stock.
